Could a Two-Drug combo beat standard care for BPH?

NCT ID NCT06944145

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding raloxifene to the standard drug finasteride works better than finasteride alone for men with an enlarged prostate (BPH). About 242 adults will take either the combo or finasteride plus a placebo for 12 months. The goal is to see if the combo improves urinary symptoms more than the single drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
finasteride and raloxifene
What this could lead to
If successful, this combination could offer a more effective treatment option for men with BPH who don't respond to finasteride alone.
What could go wrong
This is a mid-stage trial with 242 participants, so results may not apply to everyone. Adding raloxifene also carries risks like blood clots, which are already listed as an exclusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BPH (BENIGN PROSTATIC HYPERPLASIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.